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Summary
Background More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. Detection of 
intracranial injuries relies on head CT, which is overused and resource intensive. Blood-based brain biomarkers 
hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. We 
sought to validate a test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein 
(GFAP), at predetermined cutoff values, to predict traumatic intracranial injuries on head CT scan acutely 
after TBI.
Methods This prospective, multicentre observational trial included adults (≥18 years) presenting to participating 
emergency departments with suspected, non-penetrating TBI and a Glasgow Coma Scale score of 9–15. Patients were 
eligible if they had undergone head CT as part of standard emergency care and blood collection within 12 h of injury. 
UCH-L1 and GFAP were measured in serum and analysed using prespecified cutoff values of 327 pg/mL and 
22 pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single test result that was compared 
with head CT results. The primary study outcomes were the sensitivity and the negative predictive value (NPV) of the 
test result for the detection of traumatic intracranial injury on head CT.
Findings Between Dec 6, 2012, and March 20, 2014, 1977 patients were recruited, of whom 1959 had analysable data. 
125 (6%) patients had CT-detected intracranial injuries and eight (<1%) had neurosurgically manageable injuries. 
1288 (66%) patients had a positive UCH-L1 and GFAP test result and 671 (34%) had a negative test result. For detection 
of intracranial injury, the test had a sensitivity of 0·976 (95% CI 0·931–0·995) and an NPV of 0·996 (0·987–0·999). 
In three (<1%) of 1959 patients, the CT scan was positive when the test was negative.
Interpretation These results show the high sensitivity and NPV of the UCH-L1 and GFAP test. This supports its 
potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at emergency 
departments in whom a head CT is felt to be clinically indicated. Future studies to determine the value added by this 
biomarker test to head CT clinical decision rules could be warranted.
Funding Banyan Biomarkers and US Army Medical Research and Materiel Command.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
An estimated 54–60 million people worldwide sustain a 
traumatic brain injury (TBI) each year.1 In the USA, TBI 
results in more than 2·5 million emergency department 
visits annually, most of these being mild TBI (also known 
as concussion).2 Head CT scan is the diagnostic modality 
of choice to evaluate patients for traumatic intracranial 
injuries,3 contributing to the approximately 20 million 
head CT scans performed annually in the USA.4 Although 
effective for detecting traumatic injuries that require 
observation or neurosurgical evacuation, the widespread 
use of head CT scanning has been questioned due 
to potential adverse effects of radiation exposure, 
unnecessary emergency department resource use, and 
cost.4–6 These factors take on added importance for 
patients with mild TBI in whom the prevalence of 
CT-detected intracranial injury is typically less than 10%.6 
Clinical decision rules (CDRs) have been developed with 
the goal of reducing unnecessary head CT scans, but they 
have had only modest impact on CT use.5,7
Prior studies have shown the potential for blood-based 
brain injury biomarkers to predict the absence of 
intracranial injury after TBI and aid in reducing 
unnecessary head CT use.8–11 Of the many different 
proteins, small molecules, and lipid products investigated 
in humans for this purpose, the S100 astroglial calcium-
binding protein B (S100B) has been the most studied. 
Although some guidelines have recommended this 
biomarker for clinical use to predict intracranial injury 
on CT,12 the 2008 American College of Emergency 
Physician guidelines for managing adult patients with 
mild TBI determined that use of S100B only had level C 
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evidence.3 Currently, no blood-based brain biomarker 
tests in the USA have been approved by the US Food and 
Drug Administration (FDA) for use outside a research 
setting. This gap in diagnostic capability has received 
much attention with many calls for advancing brain 
biomarker research.13
Several novel brain proteins have been identified that 
potentially address this gap.14 Two proteins, ubiquitin 
C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary 
acidic protein (GFAP), have emerged as promising 
candidates for translation to clinical use. Preliminary 
evidence suggesting both proteins were accurate 
predictors of CT-detected intracranial injuries were 
limited by small cohort size, variability in the timing of 
blood sample acquisition, and retrospective determi-
nation of cutoff values that probably biased the estimate 
of diagnostic accuracy.8–10,15,16
We therefore did a large, prospective, multicentre trial, 
entitled A Prospective Clinical Evaluation of Biomarkers 
of Traumatic Brain Injury (ALERT-TBI), aiming to 
validate the ability of a biomarker test combining 
UCH-L1 and GFAP, at predetermined cutoff values, to 
predict traumatic intracranial injuries on head CT scan 
within 12 h of TBI.
Methods
Study design and participants
The ALERT-TBI trial was designed to validate the ability 
of a biomarker test combining UCH-L1 and GFAP to 
predict CT-detected traumatic intracranial injuries within 
12 h of TBI. This study was done at 22 investigational 
sites globally (15 in the USA and seven in Europe; 
appendix). All sites provided approval from their 
institutional ethics committee or appropriate regulatory 
body.
Enrolled participants represented a convenience 
sample of patients aged 18 years or older presenting to 
participating emergency departments with a suspected, 
non-penetrating TBI resulting from an external force and 
a Glasgow Coma Scale (GCS) score of 9–15 at the time of 
informed consent. Because of the controversy regarding 
the clinical symptoms that define the lower bounds of 
TBI severity,17 neither loss of consciousness nor amnesia 
was a requirement for inclusion. However, patients were 
only eligible for inclusion if they underwent non-contrast 
head CT scanning within 12 h of injury as part of their 
clinical care. Additional inclusion criteria comprised 
blood sampling within 12 h of injury and provision of 
informed written consent.
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Research in context
Evidence before this study
Existing evidence suggests that head injuries formerly thought of 
as minor, such as concussion, might actually result in brain 
damage. This line of evidence comes principally from advanced 
neuroimaging studies (eg, diffusion tensor imaging, functional 
MRI, and magnetic resonance spectroscopy) over the past 
10 years revealing traumatic axonal injury not detectable on 
standard CT or MRI. Although these advanced neuroimaging tests 
are sensitive, they are expensive, not readily available, are still 
considered suitable only for research, and have not yet entered 
standard clinical practice. Consequently, more than 20 different 
brain proteins have been studied, with seven— S100 astroglial 
calcium-binding protein B (S100B), neuron-specific enolase 
(NSE), ubiquitin C-terminal hydrolase-L1 (UCH-L1), glial fibrillary 
acidic protein (GFAP), alpha-II spectrin, and tau—having 
demonstrated diagnostic accuracy for either distinguishing 
concussion from non-concussion or predicting head CT results. 
Several systematic reviews and meta-analyses of S100B have 
revealed its high sensitivity and negative predictive value (NPV) 
for acute head CT scan. The best reference standard for 
TBI-associated axonal injury, brain tissue histopathology, cannot 
be done in most patients with head injuries. However, head CT 
scans are frequently done in emergency departments to evaluate 
TBI, which made them a practical reference standard for analysing 
the diagnostic performance of a blood-based brain biomarker.
Added value of this study
Our study results showed that a serum biomarker test 
combining GFAP and UCH-L1 had a sensitivity of 97·6% and 
NPV of 99·6% for the detection of acute intracranial injuries on 
head CT scan. These findings support its potential clinical role 
for ruling out the need for a CT scan among patients presenting 
to emergency departments with TBI in whom a head CT is felt 
to be clinically indicated. Because of the large sample size and 
the methodological rigour used to conduct this study, we 
believe our estimates of the diagnostic accuracy of a combined 
GFAP and UCH-L1 biomarker test are precise with minimal bias. 
This methodological rigour was balanced by integrating 
elements of pragmatic clinical trials, which make our results 
broadly generalisable. These elements include a practical study 
definition of TBI and no strict criteria for head CT ordering 
among acute care clinicians.
Implications of all the available evidence
Combined with existing evidence, our results suggest that up to 
a third of head CT scans done in the acute setting of TBI could 
be avoided, with a very low false-negative rate. Clinical use of 
the GFAP and UCH-L1 biomarker test has the potential to 
reduce unnecessary head CT scans with their attendant 
radiation exposure and cost, but only if applied to appropriate 
patients. The results of our study pertain to the subset of 
patients with TBI thought to have a clinical need for head CT 
scanning, not to all patients with TBI. Future studies to compare 
this biomarker test to more sensitive indicators of traumatic 
axonal injury such as diffusion tensor imaging and to clinical 
recovery would bring us one step closer to the goal of 
developing improved, objective measures to aid in diagnosing 
TBI.
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A GCS score was determined at the time of consent by 
study staff trained and certified by having successfully 
passed a GCS score examination (appendix). Site 
investigators assessed patients’ decisional capacity for 
informed consent in accordance with local institutional 
review boards and ethics committee guidance. Informed 
written consent was provided by legally authorised 
representatives for those patients without decisional 
capacity. Patients were excluded if the time of injury 
could not be determined, if head CT scanning was not 
performed, if venepuncture was not feasible, or if 
informed consent was not obtainable. Additional 
exclusion criteria are provided in the appendix.
Procedures
Venous blood was processed to serum, transferred to 
cryovials, and frozen at −80°C within 1 h of collection. 
Samples were shipped on dry ice to a central repository 
and later sent to one of three core laboratories for 
analysis. Laboratory personnel were blinded to patients’ 
diagnosis and clinical status. Serum samples were 
analysed for UCH-L1 and GFAP concentration using 
chemiluminescent enzyme-linked immunosorbent 
assays. Assay results were not provided to treating health-
care providers. Results from the GFAP and UCH-L1 
assays were combined into a single qualitative test result. 
A patient’s test result was considered valid if it satisfied 
the Boolean criteria for either positive or negative. A 
negative test result was defined as both markers falling 
below their prespecified cutoff value, whereas a positive 
test result was defined as one or both markers falling 
above their prespecified cutoff value. A patient’s test 
result was invalid if the assay result for both markers was 
invalid, or if the result for one marker was invalid and 
the result for the other was below its predetermined 
cutoff value (see appendix for details).
The reportable ranges were 10–320 pg/mL for the GFAP 
assay and 80–2560 pg/mL for the UCH-L1 assay. The 
lower limit of quantification was less than 10 pg/mL for 
GFAP and less than 80 pg/mL for UCH-L1. Concentrations 
of UCH-L1 or GFAP above the reportable range were 
analysed as 2560 pg/mL and 320 pg/mL, respectively, 
whereas those below were analysed as 80 pg/mL and 
10 pg/mL, respectively. The lower limit of detection was 
not determined for either assay because the lower limit of 
quantification was found to lie below the reportable ranges 
for each assay. For both assays, the intra-run and inter-run 
coefficient of variation was less than 10%. Prespecified 
biomarker cutoff values were derived in an independent 
group of 334 adults with mild TBI defined by a GCS 13–15, 
yielding cutoff concentration values of 327 pg/mL for 
UCH-L1 and 22 pg/mL for GFAP (appendix).
Head CT scans acquired at each site were transmitted 
to a central imaging laboratory (appendix). In the case 
of multiple CT scans, the images obtained closest to 
the blood draw were analysed. Two independent, 
board-certified neuroradiologists (JYC and AV), not 
affiliated with any enrolment site, reviewed each CT scan 
and determined if it was positive, negative, or 
inconclusive for an acute traumatic intracranial injury. 
Radiologists were blinded to GFAP and UCH-L1 results 
and all clinical information except age and sex. If the two 
primary CT reviewers did not agree, the scan was 
adjudicated by a secondary reviewer (also a board-
certified neuroradiologist). A head CT scan was 
considered valid if it could be interpreted as either 
positive or negative. Patients with unreadable (defined by 
the inability to fully assess the head CT scan) or 
inconclusive head CT scans were excluded from analysis. 
Head CT scans were considered inconclusive if both 
primary readers thought the scan was inconclusive, or if 
one of the primary reviewers thought the scan was 
inconclusive and the secondary reviewer agreed.
CT-positive was defined as the presence of one or 
more of the following injuries: acute epidural haema-
toma, acute subdural haematoma, indeterminate extra-
axial haemorrhage, intraventricular haemorrhage, 
parenchymal haematoma, petechial haemorrhagic or 
bland sheer injury, subarachnoid haemorrhage, brain 
oedema, brain herniation, non-haemorrhagic contusion, 
ventricular compression, ventricular trapping, cranial 
fractures, depressed skull fractures, facial fractures, scalp 
injury, or skull base fractures. CT findings were also 
categorised as neurosurgically manageable, defined as an 
acute epidural haematoma greater than 30 cm³, acute 
subdural haematoma with a thickness greater than 
2011 participants eligible
34 did not undergo serum analysis 
 5 because injury-blood draw time interval was unknown or >12 h
 29 because no biomarker test was done
  16 no blood collected
  11 withdrawn
  2 blood samples lost
1977 had biomarker test
676 had negative biomarker test
671 had head CT scan results 1288 had head CT scan results
 3 had positive head CT scan
668 had negative head CT scan
 122 had positive head CT scan
1166 had negative head CT scan
1301 had positive biomarker test
5 had no head CT results
 4 head CT scan was not done
 1 head CT scan was unreadable
13 had no head CT scan results
 4 head CT scan was not done
 6 head CT scan was unreadable
 3 head CT scan was inconclusive
Figure 1: Trial profile
No participants had invalid (ie, inconclusive) GFAP and UCH-1L biomarker test results.
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10 mm or a midline shift greater than 5 mm, a 
parenchymal contusion greater than 50 cm³, or a frontal 
or temporal contusion greater than 20 cm³ with midline 
shift of at least 5 mm or cisternal compression.18 Inter-
rater reliability for the two primary CT reviewers was 
estimated using the κ coefficient statistic.
Outcomes
The primary study outcomes were the negative predictive 
value (NPV) and sensitivity of the UCH-L1 and GFAP 
test result for intracranial injury on head CT. Additionally, 
we determined UCH-L1 and GFAP test specificity, 
positive predictive value (PPV), and likelihood ratio 
positive (LRP) and likelihood ratio negative (LRN) values 
for the presence or absence of CT-detected intracranial 
injury and for neurosurgically manageable injury.
Statistical analysis
A minimum sample size of 107 CT-positive patients was 
required to estimate a test sensitivity of 0·95 with a lower 
95% CI bound of 0·90. This sample size provided 
80% power at p<0·05 to achieve a test sensitivity of at least 
95% and an NPV of at least 99% with a misclassification 
rate of 5%. The total number of patients needed to accrue 
107 CT-positive patients was estimated to be 2000 on the 
basis of the presumption that the prevalence of CT-
detected injuries would be between 5% and 6%. To 
determine if test accuracy was influenced by sex, a 
stratified analysis was performed by comparing the 
diagnostic performance of the biomarker test in men and 
women. Sensitivity analyses were also carried out on the 
subset of patients with GCS 14–15, because this TBI 
severity range was the focus of the two most recently 
proposed CDRs.3,12 We also analysed the subset of patients 
with neurosurgically manageable lesions on head CT.
95% CIs for sensitivity, specificity, NPV, and PPV were 
estimated using the exact (Clopper-Pearson) methods for 
proportions, and for LRN and LRP using normal 
approximation methods. Statistical significance testing 
was performed using α=0·05. All analyses were done 
using SAS version 9.4 (SAS Institute, Cary, NC, USA).
This study is registered with ClinicalTrials.gov, number 
NCT01426919.
Role of the funding source
The study was designed by the Study Steering Committee, 
the sponsor, Banyan Biomarkers, and the US FDA. Data 
collection was coordinated by Pharmaceutical Research 
Associates and Perceptive Informatics. Data analysis was 
conducted by Agility Clinical following a prespecified 
statistical analysis plan. The authors had full access to 
study data and had final responsibility for the decision to 
publish.
Results
Between Dec 6, 2012, and March 20, 2014, 2011 participants 
were enrolled, 1354 (67%) from US sites and 
657 (33%) from European sites. Of those enrolled, 34 did 
not undergo serum analysis for a variety of reasons 
(figure 1), yielding 1977 patients with biomarker test 
results. 18 of these participants did not have analysable 
head CT scans, resulting in 1959 participants with TBI 
with a valid head CT scan and test result for analysis. Of 
these, 1920 (98%) had a GCS of 14–15 (table 1). No 
All patients 
(GCS 9–15; n=1959)
Patients with 
GCS 14–15 (n=1920)
Patients with 
neurosurgically 
manageable lesions (n=8)
Age, years 48·9 (20·9, 18–98) 48·8 (20·9, 18–98) 64·3 (24·5, 21–90)
Sex
Women 852 (43%) 833 (43%) 5 (63%)
Men 1107 (57%) 1087 (57%) 3 (38%)
Race or ethnicity*
White 1369 (70%) 1334 (69%) 8 (100%)
Black or African American 529 (27%) 527 (27%) 0
Hispanic 92 (5%) 89 (5%) 0
Other or unknown 72 (4%) 70 (4%) 0
GCS score
9 2 (<1%) ·· 2 (25%)
10 0 ·· 0
11 3 (<1%) ·· 0
12 12 (1%) ·· 1 (13%)
13 22 (1%) ·· 0
14 92 (5%) 92 (5%) 0
15 1828 (93%) 1828 (95%) 5 (63%)
Mechanism of injury†
Acceleration or 
deceleration
413 (2%) 408 (21%) 3 (38%)
Motor vehicle accident 606 (31%) 598 (31%) 3 (38%)
Pedestrian struck by vehicle 69 (4%) 69 (4%) 0
Fall 1010 (52%) 981 (51%) 6 (75%)
Explosion 3 (<1%) 3 (<1%) 0
Assault 185 (9%) 183 (10%) 0
Sports Injury 48 (2%) 47 (2%) 0
Other 52 (3%) 52 (3%) 0
Unknown 126 (6%) 123 (6%) 0
Loss of consciousness
Yes 825 (42%) 803 (42%) 5 (63%)
No 1035 (53%) 1026 (53%) 3 (38%)
Unknown 99 (5%) 91 (5%) 0
Post-traumatic amnesia
Yes 645 (33%) 626 (33%) 3 (38%)
No 1282 (65%) 1271 (66%) 2 (25%)
Unknown 32 (2%) 23 (1%) 3 (38%)
Intoxicated with alcohol or drugs
Yes 416 (21%) 402 (21%) 2 (25%)
No 1528 (78%) 1504 (78%) 5 (63%)
Unknown 15 (1%) 14 (1%) 1 (13%)
Head CT scan
Traumatic injury 125 (6%) 113 (6%) 8 (100%)
No traumatic injury 1834 (94%) 1807 (94%) 0
(Table 1 continues on next page)
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participants died during the study investigation period 
(time of consent until 24 h after injury or emergency 
department discharge, whichever came first).
125 (6%) participants with TBI had a traumatic 
intracranial injury on head CT (table 2), and 
eight (<1%) had neurosurgically manageable lesions. The 
prevalence of intracranial injury was slightly lower 
among patients with a GCS of 14–15 (table 2). The most 
common head CT finding was subarachnoid 
haemorrhage, followed by acute subdural haematoma 
and parenchymal haematoma. The distribution of CT 
findings was similar in the subset of patients with a GCS 
of 14–15 (table 2). Among patients with neurosurgically 
manageable lesions, acute subdural haematoma was the 
most common finding followed by ventricular 
compression and subarachnoid haemorrhage. Inter-rater 
reliability for head CT scan interpretation was 
0·73 (95% CI 0·67–0·80; appendix). The two primary 
reviewers were in agreement for 1899 (97%) of head CT 
scans; the secondary reviewer adjudicated the remaining 
60 (3%) scans. Of these 60 scans, the secondary reviewer 
judged 37 to be CT positive, and 23 to be CT negative. A 
sensitivity analysis to estimate the potential effect of 
disagreement among the neuroradiology reviewers can 
be found in the appendix.
Patients underwent blood draw a median of 3·2 h after 
injury (table 1). Among all patients, both GFAP and 
UCH-L1 concentrations were significantly higher among 
those who were CT positive compared with those who 
were CT negative (median GFAP 135·0 pg/mL vs 
22·2 pg/mL; p<0·0001; median UCH-L1 604·8 pg/mL vs 
261·0 pg/mL; p<0·0001; figure 2). Among all patients 
with TBI, 1288 (66%) had a positive test and 671 (34%) had 
a negative test (appendix). Overall test sensitivity was 
0·976 (95% CI 0·931–0·995) and NPV was 
0·996 (0·987–0·999) for acute intracranial injury 
(table 3). Three patients had false-negative test results 
(appendix); however, one of these patients might have 
been a false CT positive, because a follow-up MRI showed 
an underlying cavernous malformation, a vascular defect 
that can mimic a focal haemorrhagic contusion on CT. 
The test performed similarly among patients with 
GCS 14–15 (figure 2), and had slightly better performance 
among the 39 patients with a GCS 9–13 (sensitivity 1·00, 
95% CI 0·74–1·0; NPV 1·00, 0·48–1·0). The performance 
of the test among men was numerically higher than that 
for women, although the difference was not significant 
(appendix). The test was 100% sensitive with a 100% NPV 
for detecting neurosurgically manage able lesions 
(table 3). A sensitivity analysis comparing the diagnostic 
accuracy of the biomarker test to each protein individually 
among a subset of 1790 patients having quantitative 
values for both GFAP and UCH-L1 proteins revealed 
that, with respect to the primary outcomes, the 
combination of both proteins outperformed each 
marker separately, but that the diagnostic improvement 
over GFAP alone was not significant (appendix).
Discussion
The development of a clinically validated brain biomarker 
test has the potential to substantially alter diagnostic 
approaches to patients with TBI in acute care settings. In 
All patients 
(GCS 9–15; n=1959)
Patients with 
GCS 14–15 (n=1920)
Patients with 
neurosurgically 
manageable lesions (n=8)
(Continued from previous page)
Assay
Time from injury to blood draw, h
Median 3·2 (2·3–4·0) 3·2 (2·3–4·0) 3·4 (2·6–5·2)
Range 0·3–11·9 0·3–11·9 1·1–7·8
GFAP, pg/mL‡
Median 24·3 (10·0–57·4) 24·1 (10·0–55·4) 105·3 (40·7–320·0)
Range 10·0–320·0 10·0–320·0 40·6–320·0
UCH-L1, pg/mL§
Median 273·1 (151·7-535·5) 270·1 (150·3–530·6) 963·6 (452·7–2560·0)
Range 80·0–2560·0 80·0–2560·0 208·1–2560·0
Data are n (%), mean (SD, range), and median (IQR), unless stated otherwise. GCS=Glasgow Coma Scale. 
UCH-L1=ubiquitin C-terminal hydrolase-L1. GFAP= glial fibrillary acidic protein. *Patients could choose more than one 
race. †Patients could have more than one mechanism of injury. ‡Assessed in 1819 patients (1787 with GCS 14–15 and 
six with neurosurgically manageable lesions). §Assessed in 1915 patients (1876 with GCS 14–15 and eight with 
neurosurgically manageable lesions).
Table 1: Patient demographics and characteristics
All patients 
(GCS 9–15; 
n=125*)
Patients with 
GCS 14–15 
(n=113†)
Patients with 
neurosurgically 
manageable 
lesions (n=8)
Haemorrhagic lesions
Acute epidural haematoma 12 (10%) 10 (9%) 2 (25%)
Acute subdural haematoma 60 (48%) 55 (49%) 8 (100%)
Indeterminate extra-axial haemorrhage 19 (15%) 17 (15%) 1 (13%)
Intraventricular haemorrhage 7 (6%) 6 (5%) 0
Parenchymal haematoma 27 (22%) 22 (19%) 3 (38%)
Petechial haemorrhagic or bland sheer injury 4 (3%) 3 (3%) 1 (13%)
Subarachnoid haemorrhage 76 (61%) 64 (57%) 5 (63%)
Non-haemorrhagic lesions
Brain oedema 12 (10%) 8 (7%) 3 (38%)
Brain herniation 4 (3%) 2 (2%) 3 (38%)
Non-haemorrhagic contusion 8 (6%) 6 (5%) 1 (12%)
Ventricular compression 13 (10%) 10 (9%) 6 (75%)
Ventricular trapping 1 (1%) 0 1 (13%)
External or skull injuries‡
Cranial fractures 35 (28%) 29 (26%) 3 (38%)
Depressed skull fractures 4 (3%) 3 (3%) 0
Facial fractures 24 (19%) 20 (18%) 2 (25%)
Scalp injury 121 (97%) 109 (96%) 6 (75%)
Skull base fractures 21 (17%) 16 (14%) 3 (38%)
CT-positive indicates presence of traumatic intracranial injury on head CT. GCS=Glasgow Coma Scale. *Includes 
eight patients with neurosurgically manageable lesions. †Includes five patients with neurosurgically manageable 
lesions. ‡External or skull injuries were not used to define a CT-positive result.
Table 2: CT findings in participants with traumatic intracranial injury, by Glasgow Coma Scale category
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what is, to our knowledge, the largest TBI biomarker trial 
to date, we report the high sensitivity of a novel serum-
based test for the detection of traumatic intracranial 
injuries on head CT within 12 h of injury. A test 
combining GFAP and UCH-L1 assays at prespecified cut-
off concentrations had a sensitivity of 0·976 and an NPV 
of 0·996 with a specificity of 0·364 for prediction of acute 
CT-detected intracranial injury in our study population, 
with similar performance (sensitivity of 0·973, NPV of 
0·995, and specificity of 0·367) among the subset with a 
GCS 14–15. Results from this study were used to support 
a request to the US FDA for commercialisation of this 
test, which was granted on Feb 14, 2018.
Currently, many acute health-care providers use CDRs 
to determine patients with head injuries requiring head 
CT scan. Similar to the GFAP and UCH-L1 test, these 
CDRs are also sensitive for detection of intracranial 
injury.19 However, studies suggest that CDRs have had 
little effect on reducing unnecessary head CT use5,7 and 
might result in increased use of CT scans.20 Obstacles to 
CDR use include time and effort required to properly 
administer them and a perception that they rely on 
subjective variables that might be difficult to reliably 
obtain from a broad range of patients.21
Despite widespread recognition that development of 
blood-based brain biomarkers is important,13 no clinically 
useable test is available in North America. S100B, which 
has comparable sensitivity and NPV11,22 and is in clinical 
use in several countries in Europe,12 has been shown to 
identify patients at low risk for traumatic injuries on CT.11 
However, S100B has not been approved by the US FDA for 
this use, and neither the American College of Emergency 
Physicians3 nor the Eastern Association of Surgery of 
Trauma23 recommends its use as a pre-head CT screen.
The GFAP and UCH-L1 test performed as well among 
patients with a GCS of 14–15 as it did in the entire cohort 
(GCS of 9–15). Despite the favourable results for use of 
this test across GCS ranging from 9 to 15, clinicians might 
be reluctant to withhold head CT scanning in patients 
with TBI with a GCS less than 14 (indicating more severe 
TBI). Patients with a GCS of 14–15 represent a challenge 
to acute care clinicians. They might appear neurologically 
normal but most CDRs recommend scanning both those 
with a persistent GCS of 14 and a subset of those with a 
GCS of 15.19 It is in patients with GCS of 14–15 that the use 
of a biomarker test could be of greatest value. In the 
current study, 666 (35%) of 1920 patients with a GCS 
of 14–15 had a negative test result, representing the 
proportion of patients thought to be in clinical need of a 
head CT in whom scanning could potentially have been 
avoided.
Our results have several important implications. First, 
clinical use of the GFAP and UCH-L1 test could 
substantially reduce head CT use. If the GFAP and 
UCH-L1 test were used in patients with TBI in whom a 
head CT scan was felt to be clinically indicated, those 
with a negative test (34–35% among all patients with TBI 
and those with GCS 14–15) would not undergo CT scan. 
Thus, by imaging only those with a positive GFAP and 
UCH-L1 test, overall scanning could be reduced by about 
a third. The extent to which these results can be applied 
to patients with GCS 9–13 is uncertain. Although the 
point estimates for both sensitivity and NPV was 1·00, 
the small number of patients in this group produced 
wide 95% CIs. Until the precision of these point 
estimates can be confirmed by appropriately powered 
studies, caution should be used in applying these 
results to patients with TBI with GCS 9–13.
Second, the observation that there were ten times as 
many positive GFAP and UCH-L1 tests as positive CT 
scans among patients with head injuries suggests that 
these two proteins might be detecting more subtle 
degrees of injury not visible on CT scan. In support of 
this idea, a preliminary study24 of nine patients with mild 
TBI reported significantly elevated GFAP levels among 
those with haemorrhage on MRI, including one with a 
normal head CT scan. In a study of 38 patients with head 
injuries with normal CT scans, elevated plasma levels of 
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Figure 2: (A) Serum GFAP and (B) UCH-L1 levels by head CT result
The upper and lower bounds of each box indicate the 75th and 25th percentiles, respectively. Within each box, the 
square marker symbol indicates the mean and the horizontal line indicates the median. Whiskers extend up to 
1·5 × IQR (bounded by observed minimum and maximum). Small circles indicate actual datapoints, staggered by 
patient. Dotted horizontal lines represent prespecified cutoff value. UCH-L1=ubiquitin C-terminal hydrolase-L1. 
GFAP=glial fibrillary acidic protein. GCS=Glasgow Coma Scale.
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the neuronal protein spectrin N-terminal fragment 
correlated with fractional anisotropy changes on diffusion 
tensor imaging and with cognitive impairment persisting 
longer than 3 months.25 Future studies to compare GFAP 
and UCH-L1 profiles with more sensitive indicators of 
traumatic brain injury such as diffusion tensor imaging 
and with clinical recovery are probably warranted.
The current study has several limitations. We did not 
evaluate the GFAP and UCH-L1 test’s predictive ability 
for clinical outcomes such as prolonged post-concussive 
symptoms, cognitive impairment, or decreased functional 
status. Furthermore, although patients with TBI with 
extracranial injuries were eligible for study inclusion, we 
did not evaluate the impact of these injuries on test 
performance. Although trauma-related release from non-
brain tissue is a well described problem for S100B,11 
several studies have been unable to detect an effect of 
extracranial injuries on the performance of GFAP and 
UCH-L1.15,16 The advantage of including those with 
extracranial injuries in our study is the enhanced external 
generalisability of our results.
Although we examined the GFAP and UCH-L1 test 
performance among those with neurosurgically manage-
able lesions, we did not evaluate its performance among 
those actually undergoing neurosurgery. Moreover, we 
did not compare the performance of the GFAP and 
UCH-1 test to CDRs. Although a number of clinical 
variables were collected that could potentially allow for a 
post-hoc determination of which patients did or did not 
meet CDR criteria, such a retrospective analysis would 
not meet accepted methodological standards performing 
CDR-related research and would be considered 
exploratory.26 These standards should be integrated in a 
future study with the express aim of comparing CDRs 
with biomarker tests. We did not attempt to improve the 
test’s diagnostic accuracy by adding other clinical 
variables, although performance did not appear to vary 
by sex. Because a methodological strength of this study 
was the use of prespecified marker cutoffs, we chose not 
to explore alternative cutoffs. Nor did we compare the 
performance of the GFAP and UCH-1 test to S100B, 
which has comparable sensitivity and NPV.11,22 This study 
did not look at turnaround time for test results, and it is 
axiomatic that for a pre-head CT screening test to be 
useful, the results need to be rapidly available. Finally, 
although the independent neuroradiologists interpreting 
the head CT scans agreed on approximately 97% of cases, 
the κ was 0·73, which some might consider low. This 
might be due in part to the use of three interpretation 
categories (positive, negative, and inconclusive) rather 
than the more often used two categories (positive and 
negative). Moreover, a κ of 0·73 is actually higher than 
prior reports of agreement among reviewers interpreting 
head CT scans.27
Another final important study limitation involves the 
sensitivity analysis comparing the diagnostic perfor-
mance of the biomarker test to its component proteins. 
Because this analysis contained a subset of patients, it 
had reduced power to detect small differences in the 
primary outcomes and was probably biased due to 
dependence of participant inclusion on results of the 
test. In support of this, the CT-positive prevalence among 
the 179 participants excluded by this sensitivity analysis 
(10%) was considerably higher than among those 
included (6%). Although these results raise the possibility 
that GFAP alone might perform as well as the two 
proteins combined, they require further validation.
In summary, our results show the high sensitivity and 
NPV of a brain biomarker test combining UCH-L1 and 
GFAP for traumatic intracranial injuries on head CT 
scan. These results support the potential clinical role of 
this biomarker test for ruling out the need for a head CT 
scan among patients with TBI presenting at emergency 
departments in whom a head CT is felt to be clinically 
indicated.
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